Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Consensus Recommendation of “Reduce” by Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has earned an average rating of “Reduce” from the eleven ratings firms that are covering the firm, Marketbeat reports. Five analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $23.5667.

A number of equities analysts have recently issued reports on FMS shares. Truist Financial set a $25.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 4th. Sanford C. Bernstein increased their target price on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a report on Thursday, August 6th. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Finally, Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in FMS. Pzena Investment Management LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 2.0% in the 1st quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after acquiring an additional 299,986 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% in the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares in the last quarter. Integral Health Asset Management LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% in the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $15,483,000 after purchasing an additional 200,000 shares in the last quarter. Moran Wealth Management LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the first quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock valued at $7,846,000 after purchasing an additional 83,311 shares during the last quarter. Finally, Quantinno Capital Management LP increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 15.7% during the 1st quarter. Quantinno Capital Management LP now owns 341,343 shares of the company’s stock worth $7,701,000 after purchasing an additional 46,428 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Price Performance

Fresenius Medical Care AG & Co. KGaA stock opened at $22.66 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.02 and a 1-year high of $27.64. The company has a market cap of $12.17 billion, a PE ratio of 11.74, a price-to-earnings-growth ratio of 4.21 and a beta of 0.76. The stock’s 50 day moving average price is $23.86 and its 200 day moving average price is $23.06.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%.The firm had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.48 billion. On average, sell-side analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current fiscal year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.